Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2017-03-01 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
FDA godkender ALKs tabletvaccine mod husstøvmideallergi (ACARIZAX® i Europa)
Regulatory Filings Classification · 95% confidence The document is a company release (No 6/2017) announcing the FDA approval of a specific pharmaceutical product (HDM SLIT-tablet). It provides details on the regulatory milestone, the product's indication, and the company's strategic outlook regarding the US market. It does not fit into specific financial reporting categories like 10-K or ER, nor is it a report publication announcement. As a general corporate regulatory announcement regarding business operations and product approvals, it falls under the RNS (Regulatory Filings) category.
2017-03-01 English
Regulatory Filings 2017
Regulatory Filings Classification · 100% confidence The document is a press release from ALK dated February 16, 2017, announcing that their European marketing authorization application (MAA) for a tablet vaccine against ragweed allergy has been accepted for review via the decentralized procedure. It details the indication, the basis of the application (North American data), quotes the CEO, discusses the prevalence of ragweed allergy, and provides timelines for the expected approval and launch. This content is a specific corporate announcement regarding regulatory progress and product development, not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS). It best fits the category for updates on financing, capital structure, or significant corporate actions that aren't explicitly covered elsewhere. However, since it is a specific announcement about a regulatory submission/acceptance, and not a general financial report, it is closest to a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the regulatory approval is viewed as a major corporate milestone impacting future revenue. Given the options, and the nature of the announcement being a specific regulatory step rather than a general financial disclosure, RNS (Regulatory Filings - general fallback) is the most appropriate fit, as it is a formal announcement to the market about a regulatory event that doesn't fit the other specific categories like ER, 10-K, or DIV. It is not a proxy statement (PSI), director dealing (DIRS), or management discussion (MDA). Since it is a formal announcement of a regulatory event, RNS is the best fit among the provided codes.
2017-02-16 Danish
Regulatory Filings 2017
Regulatory Filings Classification · 100% confidence The document is an announcement from ALK stating that a regulatory filing for their ragweed sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by European health authorities via the Decentralised Procedure. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER). It specifically discusses the acceptance of a regulatory submission for a product, which falls under general corporate or regulatory news. Since it is a specific announcement about a regulatory submission process, and not a general miscellaneous filing (RNS), it best fits the category for legal/regulatory updates concerning product development or approval processes. However, none of the provided categories perfectly capture 'Regulatory Submission Acceptance'. Given the options, 'LTR' (Legal Proceedings Report) is too specific to lawsuits. 'RPA' (Report Publication Announcement) is for announcing the release of a report, not the acceptance of a filing. 'RNS' (Regulatory Filings) is the most appropriate fallback for significant, non-financial regulatory milestones that don't fit other specific categories like M&A or Capital Changes. The document is short and announces a regulatory event, making RNS a strong candidate if a more specific regulatory event code isn't available.
2017-02-16 English
ALK indsender registreringsansøgning for tabletvaccinen mod ragweedallergi i Europa
Regulatory Filings Classification · 95% confidence The document is a company release (No 5/2017) announcing that ALK has submitted a registration application for a ragweed SLIT-tablet to European health authorities. It describes the regulatory filing status, the clinical data supporting the application, and the strategic implications for the company. It does not fit into specific categories like financial reports, dividends, or board changes, and acts as a general corporate regulatory announcement regarding product development and regulatory progress. Therefore, it is classified as a Regulatory Filing (RNS).
2017-02-16 English
ALK indsender registreringsansøgning for tabletvaccinen mod ragweedallergi i Europa
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse nr. 5/2017) from ALK regarding the submission of a registration application for a ragweed allergy tablet vaccine in Europe. It is a regulatory announcement regarding company operations and product development status, which does not fit into specific categories like financial reports, dividends, or board changes. Therefore, it is classified as a general regulatory filing.
2017-02-16 English
AGM Information 2017
AGM Information Classification · 98% confidence The document is explicitly titled 'Indkaldelse til generalforsamling' (Notice of General Meeting) and details the agenda for the 'Ordinær generalforsamling i ALK-Abelló A/S den 15. marts 2017' (Annual General Meeting in ALK-Abelló A/S on March 15, 2017). The agenda covers standard AGM items like board elections, auditor election, and approval of remuneration guidelines and dividend proposals. This content directly relates to the preparation and notice for the Annual General Meeting. Although it contains remuneration details (which might suggest DEF 14A), the primary context and structure are that of an official AGM notice, which aligns best with AGM-R (AGM Information) or potentially PSI (Proxy Solicitation & Information Statement) if it were soliciting votes, but given the direct announcement of the meeting details and agenda, AGM-R is the most fitting primary classification for the notice itself, as it is the core material for the AGM.
2017-02-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.